360° Coverage : Paid Rheumatoid Arthritis (RA) Clinical Trial Now Enrolling at...

1 Updates

Paid Rheumatoid Arthritis (RA) Clinical Trial Now Enrolling at Achieve Clinical Research in Birmingham, Alabama; Accepting M/F Patients with RA Age 18 - 75

Oct 16 2013, 4:18pm CDT | by PR.com

Achieve is conducting a study to evaluate the safety and efficacy of a new drug versus rituximab in patients with moderately to severely active rheumatoid arthritis (RA).

Birmingham, AL, October 16, 2013 --(PR.com)-- *To see if you qualify for this RA Clinical Trial in Alabama, visit Achieve Clinical Research on the web (http://www.achieveclinical.com/). There is...

Filed under: news

YouTube Videos

 
 
 

45 weeks ago

Paid Rheumatoid Arthritis (RA) Clinical Trial Now Enrolling at Achieve Clinical Research in Birmingham, Alabama; Accepting M/F Patients with RA Age 18 - 75

Oct 16 2013, 4:18pm CDT | by PR.com

Achieve is conducting a study to evaluate the safety and efficacy of a new drug versus rituximab in patients with moderately to severely active rheumatoid arthritis (RA).

Birmingham, AL, October 16, 2013 --(PR.com)-- *To see if you qualify for this RA Clinical Trial in Alabama, visit Achieve Clinical Research on the web (http://www.achieveclinical.com/). There is no cost to participate, no insurance is required, and you may receive compensation for time and travel.

Study Design

This is a 48-week, double-blind, multiple dose, parallel group trial to compare the safety, efficacy, immunogenicity and tolerability of an experimental drug to Rituxan and MabThera in patients with moderately to severely active RA. Patients will be enrolled across 250 clinical sites, in 26 countries.

Part I (48-week duration) will include 150 patients, which is considered sufficient for pharmacokinetics (PK) testing. Part II consists of a 48-week comparative safety/efficacy analyses with an additional 150 patients.

Background & Rationale

Rheumatoid arthritis (RA) is a chronic systemic inflammatory disease characterized by synovial inflammation in the joints and consequently, progressive joint destruction. Depending on the severity of the disease, systemic manifestations may occur including lung disease, rheumatoid nodules and cardiovascular system effects. Without effective RA treatment, this disease may lead to severe functional disabilities, and therefore a considerable reduction in quality of life for the patient. The prevalence of RA varies with factors such as gender, race and smoking status and is approximately 0.5-1%.

B lymphocytes (B cells) are thought to play a crucial role in the pathogenesis of RA. They are also the primary source of rheumatoid factors (RFs) and anti-cyclic citrullinated peptide (anti-CCP) antibodies which contribute to the formation of immune complexes and complement activation in inflamed joints. Thus, B cell targeted therapy could play an important role in RA through a reduction in the B cell count as well as a reduction in B cell-mediated downstream effects on other cell types involved in the inflammatory response.

Primary Objectives

The primary objectives of this trial are:

To show PK similarity of this new drug to MabThera and Rituxan and of Rituxan to MabThera (three-way PK similarity).
To establish statistical equivalence of efficacy of this new drug and Rituxan/MabThera, in patients with moderately to severely active RA

Inclusion Criteria

Male or female participants, between 18 and 80 years of age, who have a diagnosis of moderately to severely active RA for at least 6 months

Patients must have had an inadequate response or intolerance to conventional DMARD therapy including at least one TNF inhibitor.

Positive for RF and/or anti-CCP antibodies.

Current treatment for RA on an outpatient basis:

-- Must be currently receiving and tolerating oral or parenteral MTX therapy at a dose of 15-25 mg per week (dose may be as low as 10 mg per week if the patient is unable to tolerate a higher dose) for at least 12 weeks immediately prior to Day 1.

-- Patients must be willing to receive oral folic acid (at least 5 mg/week or as per local practice) or equivalent during the entire study (mandatory co-medication for MTX treatment).

-- Biologic agents and DMARDs (other than MTX) must be withdrawn at least 2 weeks prior to Day 1.

-- Leflunomide must be withdrawn at least 8 weeks prior to Day 1 or a minimum of 2 weeks prior to Day 1 if after 11 days of standard cholestyramine washout.

-- If receiving current treatment with oral corticosteroids (other than intra-articular or parenteral), the dose must not exceed 10 mg/day prednisolone or equivalent. During the 4 weeks prior to Baseline (Day 1) the dose must remain stable.

-- Intra-articular and parenteral corticosteroids are not permitted within 6 weeks prior to Baseline Day 1 or throughout the trial, with the exception of IV administration of 100 mg methylprednisolone 30 to 60 minutes prior to each infusion
as this is part of the trial procedures.

-- Any concomitant non-steroidal anti-inflammatory drugs (NSAIDs) must be stable for at least 2 weeks prior to Day 1.

-- Patients may be taking oral hydroxychloroquine provided that the dose is not greater than 400 mg/day or chloroquine provided that the dose is not greater than 250 mg/day.

*Achieve Clinical Research conducts Phase II-IV Clinical Trials in Alabama. For more information about participating in an RA Clinical Study, please visit our website or contact us directly at (205) 380-6434.

Contact Information:
Achieve Clinical Research
Lashondra Cade
(205) 380-6434 320
Contact via Email
www.achieveclinical.com

Read the full story here: http://www.pr.com/press-release/520216

Press Release Distributed by PR.com

Source: PR.com

 

Don't miss ...

 

blog comments powered by Disqus

Latest stories

Use hollow-head toothbrush? Junk it now
New York, Aug 29 (IANS) After reading this news, go check your toothbrush type. According to research, solid-head toothbrushes retain less bacteria compared to hollow-head toothbrushes.
 
 
Electric currents may boost memory
New York, Aug 29 (IANS) Electric currents could be the key to treating memory impairments caused by conditions such as stroke, early-stage Alzheimer's disease, traumatic brain injury, cardiac arrest and the memory problems that occur in healthy ageing.
 
 
How movement affects hearing
New York, Aug 29 (IANS) Ever wondered why we stop moving when we carefully want to listen to someone? This, scientists have found, is not just to prevent unwanted sounds generated by our own movements.
 
 
Chinese herbal drug sends Australian woman to hospital
Melbourne, Aug 29 (IANS) A Chinese herbal medicine meant for back pain triggered life-threatening heart condition for an Australian woman, physicians reported.
 
 
 

Latest from the Network

Pakistani Army chief to meet PM
Islamabad, Aug 29 (IANS) After holding talks with leaders of the Pakistan Tehreek-e-Insaf (PTI) and the Pakistan Awami Tehreek (PAT) Friday, army chief General Raheel Sharif is scheduled to meet Prime Minister Nawaz...
Read more on Politics Balla
 
US midfielder Freddy Adu sues Brazilian club
Rio de Janeiro, Aug 29 (IANS) US footballer Freddy Adu has launched legal action against his former Brazilian club Bahia over alleged unpaid wages. The 25-year-old former child prodigy is suing the Brazilian outfit...
Read more on Sport Balla
 
Iceland volcano eruption triggers red alert
London, Aug 29 (IANS) The Icelandic Met Office raised its aviation warning level near the Bardarbunga volcano to red after an eruption began, BBC reported Friday. Scientists said a fissure eruption one-km-long started...
Read more on Politics Balla
 
Over three million fled Syria: UN
London, Aug 29 (IANS) The UN Refugee Agency (UNHCR) Friday announced that over three million Syrians have been registered as refugees and the crisis is only getting worse, BBC reported. The UNHCR said Syria is now "...
Read more on Politics Balla
 
Splitsville for Britney Spears, David Lucado
Los Angeles, Aug 29 (IANS) Pop star Britney Spears has split from her boyfriend David Lucado. The star made the announcement via a post on Twitter which read: "Ahhhh the single life!" Spears has stayed quiet on the...
Read more on Celebrity Balla
 
Valverde wins first mountain stage to retake Vuelta lead
Madrid, Aug 29 (IANS) The first mountain stage of the Vuelta de Espana cycling race produced the expected big changes to the leadership board as Alejandro Valverde took both the stage and the overall leader's red...
Read more on Sport Balla
 
Use hollow-head toothbrush? Junk it now
New York, Aug 29 (IANS) After reading this news, go check your toothbrush type. According to research, solid-head toothbrushes retain less bacteria compared to hollow-head toothbrushes. During the study, researchers...
Read more on Business Balla
 
Electric currents may boost memory
New York, Aug 29 (IANS) Electric currents could be the key to treating memory impairments caused by conditions such as stroke, early-stage Alzheimer's disease, traumatic brain injury, cardiac arrest and the memory...
Read more on Apple Balla
 
How movement affects hearing
New York, Aug 29 (IANS) Ever wondered why we stop moving when we carefully want to listen to someone? This, scientists have found, is not just to prevent unwanted sounds generated by our own movements. This interplay...
Read more on Apple Balla
 
Chinese herbal drug sends Australian woman to hospital
Melbourne, Aug 29 (IANS) A Chinese herbal medicine meant for back pain triggered life-threatening heart condition for an Australian woman, physicians reported. The woman began experiencing facial tingling and numbness...
Read more on Business Balla